Wikidata

(Q63340185)

English

VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection

clinical trial

In more languages

Statements

title
A Randomized, Open-Label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection (English)
0 references
medical condition
hepatitis
0 references
hepatitis A
0 references
hepatitis C
0 references
country
Australia
0 references
Austria
0 references
Belgium
0 references
Brazil
0 references
France
0 references
Germany
0 references
Republic of Ireland
0 references
Mexico
0 references
Poland
0 references
Spain
0 references
Sweden
0 references
United Kingdom
0 references
start time
December 2010
0 references
end time
August 2012
0 references
number of participants
744
0 references
minimum age
18 year
0 references
maximum age
70 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q63340185&oldid=1857176756"